Taro-Doxorubicin Liposomal: may contain particulate matter
Brand(s)
Last updated
Summary
Product
Taro-Doxorubicin Liposomal
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Distribution
National
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot number |
|---|---|---|---|---|---|
| Taro | Doxorubicin Liposomal | DIN 02493020 | Suspension | Doxorubicin Hydrochloride 2 mg/mL | HAF1937A |
Issue
Affected lot may contain the presence of particulate matter.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers & Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Sun Pharmaceuticals Canada Inc (former TARO Pharmaceuticals Inc.)
130 East Drive
Brampton, ON
L6T 1C1
Published by
Health Canada
Audience
General public
Healthcare
Hospitals
Distribution
National
Recall class
Type I
Identification number
RA-77723
Get notified
Receive notifications for new and updated recalls and alerts by category.